Navigation Links
Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
Date:3/9/2010

RALEIGH, N.C., March 9 /PRNewswire/ -- Arbor Pharmaceuticals ("Arbor"), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched Pediaderm™ HC Complete Kit – an innovative new product for the comprehensive management of atopic dermatitis.  Pediaderm HC Complete Kit contains Pediaderm HC (Hydrocortisone Lotion USP 2%) and patented Pediaderm Protective Emollient with Triple Synergy Technology™. Pediaderm HC Complete Kit has been specifically developed to treat, manage, and protect the skin of children with atopic dermatitis, commonly referred to as eczema.

Atopic Dermatitis (AD) is the most common chronic inflammatory skin condition among US children, and the prevalence is increasing worldwide(1). The American Academy of Dermatology recommends the use of topical corticosteroids to treat the acute flares of AD and the concomitant use of emollients to hydrate, protect and restore the skin(2).  Importantly, the presence of certain skin pathogens – most notably Staphylococcus aureus (S. aureus) – have been shown to contribute to the worsening and persistence of AD, while also contributing to problematic skin infections(3).

"Arbor is excited to introduce this novel and comprehensive approach to the treatment and management of atopic dermatitis for children suffering from this troubling disease.  The patented Triple Synergy Technology contained within the Pediaderm Protective Emollient is a unique technology that provides an innovative approach to treating AD.   As a pediatric pharmaceutical company our mission is to introduce novel products that offer better solutions for the most common childhood illnesses.  Pediaderm HC Complete Kit represents another important step for the company in fulfilling that mission," stated Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals.  

Pediaderm HC Complete Kit is the first and only product that provides a comprehensive approach to treating and managing atopic dermatitis.  Pediaderm HC contains the lowest prescription-only dose of hydrocortisone in a child-friendly, fast-drying form and is safe to use on all ages and all areas of the body(4).  The patented Pediaderm Protective Emollient is a uniquely formulated cream specifically designed to rehydrate, replenish and restore the integrity of skin damaged by atopic dermatitis.  Importantly, Pediaderm Protective Emollient incorporates the patented Triple Synergy Technology™ which has been proven to eradicate a wide range of bacteria, fungi and viruses, including Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (MRSA), two common causes of skin infections which are often difficult to treat(5).

Pediaderm HC Complete Kit is available by prescription only at retail pharmacies across the U.S.  Pediaderm HC Complete Kit is directly promoted to U.S. pediatricians by Arbor Pharmaceuticals' specialty sales force.  Pediaderm HC Complete Kit is Arbor Pharmaceuticals' fourth product launch since the company initiated commercial operations less than two years ago.  

Important Safety Information

Pediaderm HC Complete Kit is available by prescription only.

Pediaderm HC Lotion

Pediaderm HC Lotion is for topical use only and should not be used ophthalmically.

Pediaderm HC Lotion is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Pediaderm HC is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Prolonged use may produce reversible HPA axis suppression. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Patients may experience local adverse reactions, including burning, itching, irritation, and dryness. Discontinue use and contact your healthcare professional if irritation persists.

Pediaderm Protective Emollient

Pediaderm Protective Emollient is nonsteroidal and is intended for topical use only.

Pediaderm Protective Emollient is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Discontinue use and contact your healthcare professional if irritation develops.

About Arbor Pharmaceuticals

Arbor Pharmaceuticals, headquartered in Raleigh, North Carolina, is a specialty pharmaceutical company focused exclusively on the growing pediatric market.  The company intends to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for significant pediatric conditions.  In addition to PEDIADERM™ HC COMPLETE KIT, Arbor also currently markets three nonantibiotic products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®.    

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

See www.pediaderm.com for full prescribing information.

(1) Horii KA, Simon SD, Liu DY, Sharma V. Atopic Dermatitis in Children in the United States, 1997 2004: Visit Trends, Patient and Provider Characteristic, and Prescribing Patterns. Pediatrics 2007; 120;e527-e534
(2) Hanifin J et al. Guidelines of care for Atopic Dermatitis. J Am Acad Dermatol; 2004; 50:391-404.

(3) Huang J, Abrams M, Tlougan B, Rademaker A, Paller A. Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity. Pediatric; 2009; 123; e808-e814.

(4) Wolters Kluwer Health. Medispan-PriceRx 12/2009.

(5) Data on File. Arbor Pharmaceuticals, Inc.

Xylarex, Zinotic, and Neotic are registered trademarks of Arbor Pharmaceuticals, Inc.

SOURCE Arbor Pharmaceuticals

Back to top

RELATED LINKS
http://www.arborpharma.com

'/>"/>

SOURCE Arbor Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harbor BioSciences to Receive Patent for Apoptone(R) Cancer Treatment
2. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
3. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC
4. Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services
5. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
6. DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
7. ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay(TM)
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
10. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
11. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):